News

PEER VIEWPOINT: Respiratory Symptoms in Advanced Lung Cancer: A Persistent Challenge

Drs. McCannon and Temel have written an interesting review on the management of respiratory symptoms in advanced lung cancer patients. Their article is structured in a systematic, easy-to-follow format and will be a useful tool for physicians caring for patients with advanced lung cancer.



 

Respiratory Symptoms in Advanced Lung Cancer: A Persistent Challenge

  • Ahmed Elsayem, MD
  • http://dx.doi.org/10.1016/j.suponc.2011.10.004

Drs. McCannon and Temel have written an interesting review on the management of respiratory symptoms in advanced lung cancer patients. Their article is structured in a systematic, easy-to-follow format and will be a useful tool for physicians caring for patients with advanced lung cancer.

The authors reviewed up-to-date literature on frequent complications of advanced lung cancer such as pulmonary embolism, pleural effusion, pericardial tamponade, postobstructive pneumonia, and treatment-related pneumonitis (resulting from radiation therapy and certain types of chemotherapy). They also provide useful recommendations and suggest practical interventions which are supported by evidence from the literature. Clinicians caring for such patients must have a comprehensive knowledge of such complications to make a diagnosis and provide specific treatment.

Drs. McCannon and Temel address common symptoms associated with advanced lung cancer. In addition to their comprehensive review of the management of dyspnea, they address other symptoms such as cough and hemoptysis and provide specific recommendations on the management of each symptom with supportive evidence from the literature for each intervention.

Recommended Reading

Multiparametric Magnetic Resonance Imaging Identifies Candidates for Prostate Cancer Surveillance
MDedge Hematology and Oncology
Pre-Anthracycline-Based Chemo Cardiac Imaging Questioned
MDedge Hematology and Oncology
We Asked, They Answered: What Is Palliative Care?
MDedge Hematology and Oncology
FDA Issues One REMS for All Transmucosal Fentanyl
MDedge Hematology and Oncology
Program Curbs Shoulder Morbidity Post Breast Cancer
MDedge Hematology and Oncology
Heparin Bridging Associated With Increased Bleeding Risk
MDedge Hematology and Oncology
IGF-I Doesn't Predict Late Complications in Childhood Cancer Survivors
MDedge Hematology and Oncology
Prostate Cancer Deaths: Annual Screen Not Superior to Usual Care
MDedge Hematology and Oncology
Family and Caregiver Needs Over the Course of the Cancer Trajectory
MDedge Hematology and Oncology
SURVIVORSHIP Embracing the ‘new normal’
MDedge Hematology and Oncology

Related Articles